{"id":551257,"date":"2021-07-05T16:46:01","date_gmt":"2021-07-05T16:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551257"},"modified":"2021-07-05T16:46:01","modified_gmt":"2021-07-05T16:46:01","slug":"cystinosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cystinosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551257.html","title":{"rendered":"Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625476326.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625476326.jpeg\" alt=\"Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Cystinosis Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the cystinosis market. A detailed picture of the cystinosis pipeline landscape is provided, which includes the disease overview and cystinosis treatment guidelines.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span>&ldquo;<\/span><strong>Cystinosis Pipeline Insight<\/strong><span>&rdquo;<\/span><\/a><span> report provides comprehensive insights about key companies<\/span><span>&nbsp;and pipeline drugs in the Cystinosis pipeline landscapes. It comprises Cystinosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cystinosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cystinosis pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cystinosis Pipeline Report<\/a>:<br \/><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, etc., are developing therapies for the treatment of Cystinosis.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Emerging therapies such as <\/span><span>Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), <\/span><span>are expected to have a significant impact on the <\/span><span>&nbsp;Cystinosis <\/span><span>market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>ELX-02<\/span><span> (formerly known as NB124) is a small molecule, administered by the parenteral subcutaneous (SC) route. The molecule is under investigation for the treatment of cystinosis. It is under Phase II clinical trial.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cystinosis Clinical Trials Analysis<\/a><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-familial-intrahepatic-cholestasis-pfic-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of cystine, the oxidized dimer of the amino acid cysteine. It is a genetic disorder that follows an autosomal recessive inheritance pattern.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>For further information, refer to the detailed report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cystinosis Pipeline Therapeutics&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cystinosis Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Procysbi (cysteamine bitartrate) by Horizon Pharma<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Cystadrops (cysteamine hydrochloride) by Recordati S.p.A.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Cystaran (cysteamine hydrochloride) by Leadiant Biosciences<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Cystagon (cysteamine bitartrate) by Mylan Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Cystinosis Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major Players:<\/span><span> Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline Therapies:<\/span><span> Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cystinosis Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cystinosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cystinosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Cystinosis Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the cystinosis market. A detailed picture of the cystinosis pipeline landscape is provided, which includes the disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cystinosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551257.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-551257","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551257"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551257\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}